Weekly Analysts’ Ratings Changes for Palisade Bio (PALI)

Palisade Bio (NASDAQ: PALI) recently received a number of ratings updates from brokerages and research firms:

• 10/21/2026 – Palisade Bio had its “outperform” rating reaffirmed by Oppenheimer.
• 10/17/2026 – Palisade Bio was downgraded by Wall Street Zen from “hold” to “sell”.
• 10/13/2026 – Palisade Bio had its “buy” rating reaffirmed by HC Wainwright. They now have a $7.00 price target on the stock.
• 10/12/2026 – Palisade Bio had its “sell (e+)” rating reaffirmed by Weiss Ratings.
• 10/8/2026 – Palisade Bio is now covered by Raymond James Financial. They set an “outperform” rating and a $6.00 price target on the stock.
• 10/8/2026 – Palisade Bio is now covered by Raymond James Financial. They set an “outperform” rating and a $6.00 price target on the stock.
• 9/23/2026 – Palisade Bio had its “buy” rating reaffirmed by HC Wainwright. They now have a $7.00 price target on the stock.

Palisade Bio, Inc (NASDAQ: PALI) is a clinical-stage biopharmaceutical company focused on developing therapies for gastrointestinal diseases and complications associated with gastrointestinal surgery. The company’s research is centered on treatments intended to protect the intestinal barrier and support recovery following major medical procedures.

Palisade Bio’s lead product candidate, LB1148, is an orally administered serine protease inhibitor designed to reduce the harmful effects of digestive enzymes released during surgery or gastrointestinal injury.